[go: up one dir, main page]

NO20076317L - Sammensetning av en tienopyridinblodplateaggregeringsinhibitor - Google Patents

Sammensetning av en tienopyridinblodplateaggregeringsinhibitor

Info

Publication number
NO20076317L
NO20076317L NO20076317A NO20076317A NO20076317L NO 20076317 L NO20076317 L NO 20076317L NO 20076317 A NO20076317 A NO 20076317A NO 20076317 A NO20076317 A NO 20076317A NO 20076317 L NO20076317 L NO 20076317L
Authority
NO
Norway
Prior art keywords
composition
platelet aggregation
aggregation inhibitor
thienopyridine
thienopyridine platelet
Prior art date
Application number
NO20076317A
Other languages
English (en)
Inventor
David Brian Dziennik
Tamara Beth Edelman
Peter Lloyd Oren
Robert Louis Ternik
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076317(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20076317L publication Critical patent/NO20076317L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Formulering av en forbindelse av formel (I) for behandling og fremgangsmåter for anvendelse er fremlagt
NO20076317A 2005-06-10 2007-12-07 Sammensetning av en tienopyridinblodplateaggregeringsinhibitor NO20076317L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68918305P 2005-06-10 2005-06-10
PCT/US2006/021860 WO2006135605A2 (en) 2005-06-10 2006-06-06 Formulation of a thienopyridine platelet aggregation inhibitor

Publications (1)

Publication Number Publication Date
NO20076317L true NO20076317L (no) 2008-02-29

Family

ID=37198935

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076317A NO20076317L (no) 2005-06-10 2007-12-07 Sammensetning av en tienopyridinblodplateaggregeringsinhibitor

Country Status (34)

Country Link
US (1) US20080176893A1 (no)
EP (1) EP1896019B1 (no)
JP (1) JP2008543755A (no)
KR (2) KR20100076050A (no)
CN (1) CN101193633B (no)
AR (1) AR054283A1 (no)
AT (1) ATE441413T1 (no)
AU (1) AU2006258102B2 (no)
BR (1) BRPI0611350B8 (no)
CA (1) CA2611668C (no)
CY (1) CY1109502T1 (no)
DE (1) DE602006008942D1 (no)
DK (1) DK1896019T3 (no)
DO (1) DOP2006000126A (no)
EA (1) EA011693B1 (no)
EC (1) ECSP077984A (no)
ES (1) ES2330373T3 (no)
HR (1) HRP20090516T1 (no)
IL (1) IL187830A0 (no)
MA (1) MA29688B1 (no)
MX (1) MX2007015431A (no)
MY (1) MY151038A (no)
NO (1) NO20076317L (no)
NZ (1) NZ564003A (no)
PE (1) PE20070320A1 (no)
PL (1) PL1896019T3 (no)
PT (1) PT1896019E (no)
RS (1) RS51194B (no)
SI (1) SI1896019T1 (no)
TN (1) TNSN07466A1 (no)
TW (1) TWI318571B (no)
UA (1) UA91051C2 (no)
WO (1) WO2006135605A2 (no)
ZA (1) ZA200710697B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110201814A1 (en) * 2006-12-07 2011-08-18 Daiichi Sankyo Company Limited Method for producing solid preparation
CN101594865A (zh) * 2006-12-07 2009-12-02 第一三共株式会社 含有低取代的羟基丙基纤维素的药物组合物
CA2672134C (en) * 2006-12-07 2015-02-10 Daiichi Sankyo Company, Limited Solid medicinal preparation containing mannitol or lactose
US20090291138A1 (en) * 2006-12-07 2009-11-26 Daiichi Sankyo Company, Limited Film-coated preparation having improved stability
CN101568339A (zh) * 2006-12-07 2009-10-28 伊莱利利公司 普拉格雷的制品
KR101647842B1 (ko) * 2006-12-07 2016-08-11 다이이찌 산쿄 가부시키가이샤 저장 안정성이 개선된 의약 조성물
JP5363307B2 (ja) * 2007-03-02 2013-12-11 第一三共株式会社 高純度のプラスグレル塩酸塩の製造方法
RU2470636C2 (ru) 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
DE112009000268T5 (de) 2008-02-06 2011-06-01 Helm Ag Prasugrel-Salze mit verbesserten Eigenschaften
EP2107061A1 (en) * 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
EP2112155B1 (en) 2008-04-25 2010-09-29 Sandoz AG Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
WO2010094471A1 (en) * 2009-02-17 2010-08-26 Krka, D. D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
DK3100728T3 (da) 2009-05-13 2020-02-17 Cydex Pharmaceuticals Inc Farmaceutiske sammensætninger omfattende prasugrel og cyclodextrin-derivativ og fremgangsmåder til fremstilling og brug af samme
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2014060554A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Prasugrel formulations
WO2014060560A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
EP1298132B1 (en) * 2000-07-06 2006-11-22 Sankyo Company, Limited Hydropyridine derivative acid addition salts
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP4394873B2 (ja) * 2001-12-19 2010-01-06 武田薬品工業株式会社 酸素に不安定な化合物を含有する固形組成物およびその安定化方法
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
EP1653930B1 (en) * 2003-08-05 2007-12-19 Zentiva, a.s. Methods for the stabilization of atorvastatin

Also Published As

Publication number Publication date
PL1896019T3 (pl) 2010-01-29
MY151038A (en) 2014-03-31
DOP2006000126A (es) 2006-12-15
DK1896019T3 (da) 2009-10-26
AR054283A1 (es) 2007-06-13
KR20100076050A (ko) 2010-07-05
EP1896019B1 (en) 2009-09-02
TNSN07466A1 (en) 2009-03-17
ATE441413T1 (de) 2009-09-15
BRPI0611350B1 (pt) 2020-09-15
HK1116422A1 (en) 2008-12-24
CY1109502T1 (el) 2014-08-13
KR20080008413A (ko) 2008-01-23
EP1896019A2 (en) 2008-03-12
AU2006258102B2 (en) 2011-09-15
ZA200710697B (en) 2009-08-26
CA2611668A1 (en) 2006-12-21
EA011693B1 (ru) 2009-04-28
UA91051C2 (ru) 2010-06-25
HRP20090516T1 (hr) 2009-10-31
BRPI0611350B8 (pt) 2021-05-25
JP2008543755A (ja) 2008-12-04
AU2006258102A1 (en) 2006-12-21
DE602006008942D1 (en) 2009-10-15
CA2611668C (en) 2013-10-15
MA29688B1 (fr) 2008-08-01
PE20070320A1 (es) 2007-05-12
RS51194B (sr) 2010-10-31
WO2006135605A2 (en) 2006-12-21
TW200718420A (en) 2007-05-16
CN101193633A (zh) 2008-06-04
IL187830A0 (en) 2008-04-13
TWI318571B (en) 2009-12-21
SI1896019T1 (sl) 2010-01-29
CN101193633B (zh) 2011-12-14
ES2330373T3 (es) 2009-12-09
BRPI0611350A2 (pt) 2010-12-07
WO2006135605A3 (en) 2007-04-12
MX2007015431A (es) 2008-02-21
ECSP077984A (es) 2008-01-23
US20080176893A1 (en) 2008-07-24
PT1896019E (pt) 2009-11-19
EA200702670A1 (ru) 2008-04-28
NZ564003A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
NO20076317L (no) Sammensetning av en tienopyridinblodplateaggregeringsinhibitor
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
CY1108445T1 (el) Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
CY1107168T1 (el) Παραγωγα φαινυλοαλκανοϊκου οξεος και φαινυλοξυαλκανοϊκου οξεος ως ενεργοποιηται hppar
NO20043587L (no) Nye heterocykliske forbindelser som er aktive som inhibitorer av beta-laktamaser
EA201100189A1 (ru) Гетероарильные производные в качестве ингибиторов dgat1
JO2998B1 (ar) مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
EA201071019A1 (ru) Кристаллические формы производных фениламинопиримидина
ATE509917T1 (de) Gamma-secretase-inhibitoren
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
PE20091065A1 (es) Derivados bis-(sulfonilamino) en terapia 066
NO20085317L (no) Imidazoazepinonforbindelser
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
EA201000113A1 (ru) Пиразольные соединения
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
NO20090994L (no) 2-aminobenzoxazol karboxamider som 5HT3 modulatorer
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
UA104677C2 (ru) Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательных путей
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
CY1113916T1 (el) Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application